نتایج جستجو برای: cilostazol

تعداد نتایج: 1000  

2016
Yingqing Chen Indira Pandiri Yeonsoo Joe Hyo Jeong Kim Seul-Ki Kim Jeongmin Park Jinhyun Ryu Gyeong Jae Cho Jeong Woo Park Stefan W. Ryter Hun Taeg Chung

The selective type-3 phosphodiesterase inhibitor cilostazol and the antihyperlipidemic agent probucol have antioxidative, anti-inflammatory, and antiatherogenic properties. Moreover, cilostazol and probucol can regulate mitochondrial biogenesis. However, the combinatorial effect of cilostazol and probucol on mitochondrial biogenesis remains unknown. Endoplasmic reticulum (ER) stress is a well-k...

2017
Nobuyuki KANNO Tomohiro SUZUKI

Sick sinus syndrome (SSS) is a type of bradyarrhythmia that can lead to syncope. Cilostazol has been reported to be an effective treatment for human patients with SSS and other bradyarrhythmias. This report describes the successful long-term treatment with cilostazol in a dog with SSS. A nine-year old intact male Miniature Schnauzer presented with a history of syncopal episodes and unsteady gai...

2016

Takotsubo cardiomyopathy is a transient cardiac syndrome that involves left ventricular apical akinesis typically triggered by a significant emotional or physical stress. Here, we report a patient who presented with strong chest discomfort with left ventricular apical akinesis following cilostazol administration and was diagnosed with Takotsubo cardiomyopathy. Sudden onset of the disease immedi...

Journal: :The Annals of pharmacotherapy 2012
Alexander J Ansara Dane L Shiltz Jennifer B Slavens

OBJECTIVE To evaluate the safety and efficacy of cilostazol for secondary prevention of non-cardioembolic ischemic stroke. DATA SOURCES PubMed and MEDLINE searches were performed (January 1970-September 2011) using the key words cilostazol, antiplatelet, aspirin, acetylsalicylic acid, secondary stroke prevention, ischemic stroke, intracerebral hemorrhage, intracranial, cerebrovascular acciden...

Journal: :Circulation 1999
E Tsuchikane A Fukuhara T Kobayashi M Kirino K Yamasaki M Izumi S Otsuji H Tateyama M Sakurai N Awata

BACKGROUND Restenosis after percutaneous transluminal coronary (balloon) angioplasty (PTCA) remains a major drawback of the procedure. We previously reported that cilostazol, a platelet aggregation inhibitor, inhibited intimal proliferation after directional coronary atherectomy and reduced the restenosis rate in humans. The present study aimed to determine the effect of cilostazol on restenosi...

2013
Sang-Yong Yoo Sung-Gook Song Jae-Hwan Lee Eun-Seok Shin Jeong-Su Kim Yong-Hyun Park Jun Kim Kook-Jin Chun June-Hong Kim

BACKGROUND Although an angina attack by vasospastic angina (VSA) can usually be relieved or controlled with nitrates and calcium channel blockers (CCBs), there are some patients who cannot be controlled even by higher doses and combinations of these drugs. Cilostazol is a selective inhibitor of phosphodiesterase 3 that increases intracellular cyclic adenosine monophosphate (cAMP) contents. A st...

2016
Ha Neui Kim Chan Hee Gil Yu Ri Kim Hwa Kyoung Shin Byung Tae Choi

We investigated whether cilostazol, an activator of cyclic adenosine monophosphate (cAMP)-dependent intracellular signaling, could inhibit ultraviolet B (UVB) irradiation-induced photoaging in HR-1 hairless mice. Cilostazol decreased wrinkle formation and skin thickness in UVB-irradiated mice, as well as increased staining of collagen fibers and inhibition of reactive oxygen species (ROS) forma...

2011
Ichiro Ikushima Kazuchika Yonenaga Hironao Iwakiri Hideki Nagoshi Haruhito Kumagai Yasuyuki Yamashita

PURPOSE The purpose of this study was to assess the preventive effect of cilostazol on in-stent restenosis in patients after superficial femoral artery (SFA) stent placement. MATERIALS AND METHODS Of 28 patients with peripheral arterial disease, who had successfully undergone stent implantation, 15 received cilostazol and 13 received ticlopidine. Primary patency rates were retrospectively ana...

2015
Shuhei Tara Hirotsugu Kurobe Juan de Dios Ruiz Rosado Cameron A. Best Toshihiro Shoji Nathan Mahler Tai Yi Yong-Ung Lee Tadahisa Sugiura Narutoshi Hibino Santiago Partida-Sanchez Christopher K. Breuer Toshiharu Shinoka

OBJECTIVE Despite successful translation of bioresorbable vascular grafts for the repair of congenital heart disease, stenosis remains the primary cause of graft failure. In this study, we investigated the efficacy of long-term treatment with the antiplatelet drugs, aspirin and cilostazol, in preventing stenosis and evaluated the effect of these drugs on the acute phase of inflammation and tiss...

2015
Chairat Burusapat Janjira Paengnoi Kantang Satayasoontorn

BACKGROUND Insufficient arterial blood flow is the one cause of flap necrosis. Cilostazol is an inhibitor of phosphodiesterase III and increases cyclic AMP level in vascular smooth muscle cell causing vasodilation. Therefore, effect of cilostazol is expected to improve the viability of the flap. METHODS Double blinded randomized controlled trial was conducted. The study was to compare the sur...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید